Breaking News

Tweet TWEET

Johnson & Johnson Reports 2013 First-Quarter Results:

            Johnson & Johnson Reports 2013 First-Quarter Results:

Sales of $17.5 Billion Increased 8.5% Versus 2012 First Quarter; First-Quarter
EPS was $1.22 Excluding Special Items, 2013 First-Quarter EPS of $1.44
Increased 5.1%*

PR Newswire

NEW BRUNSWICK, N.J., April 16, 2013

NEW BRUNSWICK, N.J., April 16, 2013 /PRNewswire/ --Johnson & Johnson (NYSE:
JNJ) today announced sales of $17.5 billion for the first quarter of 2013, an
increase of 8.5% as compared to the first quarter of 2012. Operational
results increased 9.8% and the negative impact of currency was 1.3%. Domestic
sales increased 11.2%. International sales increased 6.3%, reflecting
operational growth of 8.7% and a negative currency impact of 2.4%. Sales
included the impact of the acquisition of Synthes, Inc., net of the
divestiture of the DePuy trauma business, which contributed 5.7% to worldwide
operational sales growth.

Net earnings and diluted earnings per share for the first quarter of 2013 were
$3.5 billion and $1.22, respectively. First quarter 2013 net earnings
included after-tax special items of approximately $0.6 billion, primarily
related to litigation expenses, as well as integration and transaction costs
related to the acquisition of Synthes, Inc. First quarter 2012 net earnings
included a gain from an after-tax special item of approximately $0.1 billion
as shown in the accompanying reconciliation of non-GAAP financial measures.
Excluding these special items, net earnings for the current quarter were $4.1
billion and diluted earnings per share were $1.44, representing increases of
8.0% and 5.1%, respectively, as compared to the same period in 2012.*

"We delivered solid first quarter results led by the success of many of our
recently launched pharmaceutical products and the addition of Synthes to our
orthopaedics business. Also of note is the growth in our over-the-counter
medicines business as we continue to make progress in returning a reliable
supply of high quality products to our customers," said Alex Gorsky, Chairman
and Chief Executive Officer. "Our investments to advance our pipelines and
expand our global presence, along with the outstanding efforts of our talented
people, will enable us to continue to deliver sustainable growth and
meaningful innovations to patients and customers around the world."

The Company confirmed its earnings guidance for full-year 2013 of $5.35 -
$5.45 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the first quarter represented an
increase of 2.2% versus the prior year consisting of an operational increase
of 3.3% and a negative impact from currency of 1.1%. Domestic sales increased
2.4%. International sales increased 2.1%, which reflected an operational
increase of 3.8% and a negative currency impact of 1.7%.

Positive contributors to operational results were TYLENOL^® and MOTRIN^®
analgesics and upper respiratory over-the-counter medicines; baby care
products; LISTERINE^® mouthwash; and NEUTROGENA^® skin care products. During
the quarter, Johnson & Johnson (China) Investment Co., Ltd. completed the
acquisition of Shanghai Elsker Mother & Baby Co., Ltd, a well regarded baby
care company in China, known for its position in the naturals segment.

Worldwide Pharmaceutical sales of $6.8 billion for the first quarter
represented an increase of 10.4% versus the prior year with operational growth
of 11.4% and a negative impact from currency of 1.0%. Domestic sales
increased 14.7%. International sales increased 6.1% which reflected an
operational increase of 8.1% and a negative currency impact of 2.0%.

Primary contributors to operational sales growth were INVEGA^®
SUSTENNA^®/XEPLION^® (paliperidone palmitate), a once-monthly, long-acting,
injectable atypical antipsychotic for the acute and maintenance treatment of
schizophrenia in adults; STELARA^® (ustekinumab), a biologic approved for the
treatment of moderate to severe plaque psoriasis; SIMPONI^® (golimumab), a
biologic approved to treat adults with moderate-to-severe rheumatoid
arthritis, psoriatic arthritis, and ankylosing spondylitis; REMICADE^®
(infliximab), a biologic approved for the treatment of a number of
immune-mediated-inflammatory diseases; PREZISTA^® (darunavir), a treatment for
HIV; and sales of recently launched products.

The strong sales results of recently launched products included ZYTIGA^®
(abiraterone acetate), an oral, once-daily medication for use in combination
with prednisone for the treatment of metastatic, castration-resistant prostate
cancer; XARELTO^® (rivaroxaban), an oral anticoagulant; and INCIVO^®
(telaprevir), a direct-acting antiviral protease inhibitor, for the treatment
of genotype-1 chronic hepatitis C virus.

During the quarter, the U.S. Food and Drug Administration (FDA) approved
INVOKANA™ (canagliflozin) for the treatment of adults with type 2 diabetes.
INVOKANA™ is the first in a new class of medications called sodium glucose
co-transporter 2 (SGLT2) inhibitors to be approved in the United States. In
addition, a Marketing Authorization Application was submitted to the European
Medicines Agency seeking approval for a fixed-dose therapy combining
canagliflozin and immediate release metformin to treat adult patients with
type 2 diabetes.

Also in the quarter, a New Drug Application was submitted to the FDA, as well
as regulatory health authorities in Japan, seeking approval for simeprevir
(TMC435), an investigational NS3/4A protease inhibitor, for the treatment of
genotype 1 chronic hepatitis C in adult patients. In addition, the FDA
granted Breakthrough Therapy Designations for the investigational oral agent
ibrutinib as a monotherapy for three B-cell malignancies: in patients with
relapsed or refractory mantle cell lymphoma who have received prior therapy;
in patients with Waldenstrom's macroglobulinemia; and in patients with chronic
lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short
arm of chromosome 17. Ibrutinib is jointly being developed by Janssen Research
& Development, LLC and Pharmacyclics Inc. 

Worldwide Medical Devices and Diagnostics sales of $7.1 billion for the first
quarter represented an increase of 10.2% versus the prior year consisting of
an operational increase of 11.9% and a negative currency impact of 1.7%.
Domestic sales increased 11.4%. International sales increased 9.1%, which
reflected an operational increase of 12.2% and a negative currency impact of
3.1%. Sales included the impact of the acquisition of Synthes, Inc., which
contributed approximately 14%, 17% and 12% to worldwide, domestic and
international operational sales growth, respectively, net of the divestiture
of the DePuy trauma business.

Primary contributors to operational growth were sales from the acquisition of
Synthes, Inc., in the Orthopaedics business; Biosense Webster's
electrophysiology and Cordis' endovascular products in the Cardiovascular Care
business; Vision Care's 1-Day ACUVUE^® TRUEYE and 1-Day ACUVUE^® MOIST^®
disposable contact lenses; biosurgical and international sales of energy
products in the Specialty Surgery business; and the donor screening and
clinical laboratories products in the Diagnostics business in the U.S. 

During the quarter, 510(k) clearance was received from the FDA for the
ENSEAL^® G2 Articulating Tissue Sealer, the first articulating advanced energy
device designed to allow surgeons to take a perpendicular approach to seal
vessels, as well as the ENSEAL^® G2 Cordless Tissue Sealer Device, a first of
its kind self-contained device that includes both a generator and power
source.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,000 employees at morethan 275 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are
non-GAAP financial measures and should not be considered replacements for, and
should be read together with, the most comparable GAAP financial measures. A
reconciliation of these non-GAAP financial measures to the most directly
comparable GAAP financial measures is included in the financial schedules
accompanying this press release and can be found in the Investor Relations
section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with financial analysts to
discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous
webcast of the meeting for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A
replay and podcast will be available approximately two hours after the live
webcast by visiting www.investor.jnj.com. 

Copies of the financial schedules accompanying this press release are
available at www.investor.jnj.com/historical-sales.cfm. These schedules
include supplementary sales data, a condensed consolidated statement of
earnings, reconciliation of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson & Johnson, including a
pharmaceutical pipeline of selected compounds in late stage development can be
found on the Company's website at www.jnj.com.

NOTE TO INVESTORS

(This release contains "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995. The reader is cautioned not to rely
on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary
materially from the expectations and projections of Johnson & Johnson. Risks
and uncertainties include, but are not limited to, general industry conditions
and competition; economic factors, such as interest rate and currency exchange
rate fluctuations; technological advances, new products and patents attained
by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; significant adverse
litigation or government action; impact of business combinations; financial
distress and bankruptcies experienced by significant customers and suppliers;
changes to governmental laws and regulations and domestic and foreign health
care reforms; trends toward health care cost containment; increased scrutiny
of the health care industry by government agencies; changes in behavior and
spending patterns of purchasers of health care products and services;
financial instability of international economies and sovereign risk;
disruptions due to natural disasters; manufacturing difficulties or delays;
complex global supply chains with increasing regulatory requirements; and
product efficacy or safety concerns resulting in product recalls or regulatory
action. A further list and description of these risks, uncertainties and other
factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form
10-K, as well as subsequent filings, are available online at www.sec.gov,
www.investor.jnj.com  or on request from Johnson & Johnson.  Johnson &
Johnson does not undertake to update any forward-looking statements as a
result of new information or future events or developments.)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in      FIRST QUARTER
Millions)
                                                  Percent Change
                            2013          2012    Total   Operations  Currency
Sales to customers by
segment of business
Consumer
 U.S.                    $   1,348  1,316   2.4   % 2.4         -
 International           2,327         2,279   2.1     3.8         (1.7)
                            3,675         3,595   2.2     3.3         (1.1)
Pharmaceutical
 U.S.                    3,471         3,026   14.7    14.7        -
 International           3,297         3,107   6.1     8.1         (2.0)
                            6,768         6,133   10.4    11.4        (1.0)
Med Devices & Diagnostics
 U.S.                    3,206         2,877   11.4    11.4        -
 International           3,856         3,534   9.1     12.2        (3.1)
                            7,062         6,411   10.2    11.9        (1.7)
U.S.                        8,025         7,219   11.2    11.2        -
International               9,480         8,920   6.3     8.7         (2.4)
Worldwide                   $  17,505   16,139  8.5   % 9.8         (1.3)





Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in       FIRST QUARTER
Millions)
                                                  Percent Change
                             2013         2012    Total   Operations  Currency
Sales to customers by
geographic area
U.S.                         $   8,025  7,219   11.2  % 11.2        -
Europe                       4,481        4,194   6.8     6.2         0.6
Western Hemisphere excluding 1,783        1,714   4.0     9.1         (5.1)
U.S.
Asia-Pacific, Africa         3,216        3,012   6.8     11.8        (5.0)
International                9,480        8,920   6.3     8.7         (2.4)
Worldwide                    $  17,505   16,139  8.5   % 9.8         (1.3)





Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions
Except Per Share        FIRST QUARTER
Figures)
                        2013                  2012                  Percent
                                     Percent               Percent  Increase
                        Amount       to Sales Amount       to Sales (Decrease)
Sales to customers      $ 17,505     100.0    $ 16,139     100.0    8.5
Cost of products sold   5,554        31.7     4,915        30.4     13.0
Selling, marketing and  5,223        29.8     5,015        31.1     4.1
administrative expenses
Research and            1,784        10.2     1,645        10.2     8.4
development expense
In-process research and 64           0.4      -            -
development
Interest (income)       104          0.6      130          0.8
expense, net
Other (income) expense, 515          3.0      (611)        (3.8)
net
Earnings before
provision for taxes on  4,261        24.3     5,045        31.3     (15.5)
income
Provision for taxes on  764          4.3      1,135        7.1      (32.7)
income
Net earnings            3,497        20.0     3,910        24.2     (10.6)
Net earnings per share  $   1.22            $   1.41            (13.5)
(Diluted)
Average shares          2,858.8               2,774.9
outstanding (Diluted)
Effective tax rate      17.9       %          22.5       %
Adjusted earnings
before provision for
taxes and net earnings
^(1)
Earnings before
provision for taxes on  $  5,070    29.0     $  4,928    30.5     2.9
income
Net earnings       $  4,107    23.5     $  3,804    23.6     8.0
Net earnings per   $   1.44            $   1.37            5.1
share (Diluted)
Effective tax rate 19.0       %          22.8       %
^(1)See Reconciliation of Non-GAAP Financial
Measures.





Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial
Measures
                                      First Quarter            % Incr. /
(Dollars in Millions Except Per Share 2013         2012        (Decr.)
Data)
Earnings before provision for taxes   $  4,261    5,045       (15.5)    %
on income - as reported
Litigation expenses                   529          -
Synthes integration/transaction costs 258          (117)
and currency related
In-process research and development   64           -
Other                                 (42)         -
Earnings before provision for taxes   $  5,070    4,928       2.9       %
on income - as adjusted
Net Earnings - as reported            $  3,497    3,910       (10.6)    %
Litigation expenses                   391          -
Synthes integration/transaction costs 183          (106)
and currency related
In-process research and development   42           -
Other                                 (6)          -
Net Earnings - as adjusted           $  4,107    3,804       8.0       %
Diluted Net Earnings per share - as   $  1.22    1.41        (13.5)    %
reported
Litigation expenses                   0.14         -
Synthes integration/transaction costs 0.06         (0.04)
and currency related
In-process research and development   0.02         -
Other                                 -            -
Diluted Net Earnings per share - as   $  1.44    1.37        5.1       %
adjusted
The Company believes investors gain additional perspective of underlying
business trends and results by providing a
measure of earnings before provision for taxes on income, net earnings and
diluted net earnings per share that excludes
special items in order to evaluate ongoing business
operations.





                                   

                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                                  FIRST QUARTER
                                                % Change
                                   2013   2012  Reported Operational Currency
                                                         ^(1)
CONSUMER SEGMENT ^(2)
BABY CARE
US                                 $    99    4.0%     4.0%        -
                                   103
Intl                               461    441   4.5%     7.7%        -3.2%
WW                                 564    540   4.4%     7.0%        -2.6%
ORAL CARE
US                                 158    155   1.9%     1.9%        -
Intl                               245    232   5.6%     7.3%        -1.7%
WW                                 403    387   4.1%     5.1%        -1.0%
OTC/NUTRITIONALS
US                                 436    381   14.4%    14.4%       -
Intl                               747    723   3.3%     3.9%        -0.6%
WW                                 1,183  1,104 7.2%     7.6%        -0.4%
SKIN CARE
US                                 453    453   0.0%     0.0%        -
Intl                               449    454   -1.1%    -0.4%       -0.7%
WW                                 902    907   -0.6%    -0.2%       -0.4%
WOMEN'S HEALTH
US                                 81     93    -12.9%   -12.9%      -
Intl                               320    316   1.3%     4.9%        -3.6%
WW                                 401    409   -2.0%    0.8%        -2.8%
WOUND CARE/OTHER
US                                 117    135   -13.3%   -13.3%      -
Intl                               105    113   -7.1%    -6.1%       -1.0%
WW                                 222    248   -10.5%   -10.0%      -0.5%
TOTAL CONSUMER
US                                 1,348  1,316 2.4%     2.4%        -
Intl                               2,327  2,279 2.1%     3.8%        -1.7%
WW                                 $     3,595 2.2%     3.3%        -1.1%
                                   3,675
See footnotes at end of schedule
                                   

                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                                  FIRST QUARTER
                                                % Change
                                   2013   2012  Reported Operational Currency
                                                         ^(1)
PHARMACEUTICAL SEGMENT ^(2) (4)
IMMUNOLOGY
US                                 $     1,453 12.8%    12.8%       -
                                   1,639
Intl                               565    442   27.8%    30.1%       -2.3%
WW                                 2,204  1,895 16.3%    16.8%       -0.5%
REMICADE
US                           970    882   10.0%    10.0%       -
US Exports ^(3)               349    378   -7.7%    -7.7%       -
Intl                          281    261   7.7%     9.5%        -1.8%
WW                            1,600  1,521 5.2%     5.5%        -0.3%
SIMPONI
US                            94     64    46.9%    46.9%       -
Intl                          143    52    *        *           -3.3%
WW                            237    116   *        *           -2.0%
STELARA
US                            226    129   75.2%    75.2%       -
Intl                          120    92    30.4%    31.2%       -0.8%
WW                            346    221   56.6%    57.0%       -0.4%
OTHER IMMUNOLOGY
US                            -      -     -        -           -
Intl                          21     37    -43.2%   -42.9%      -0.3%
WW                            21     37    -43.2%   -42.9%      -0.3%
INFECTIOUS DISEASES
US                                 238    242   -1.7%    -1.7%       -
Intl                               577    513   12.5%    13.5%       -1.0%
WW                                 815    755   7.9%     8.6%        -0.7%
INCIVO
US                            -      -     -        -           -
Intl                          162    132   22.7%    24.9%       -2.2%
WW                            162    132   22.7%    24.9%       -2.2%
INTELENCE
US                            47     43    9.3%     9.3%        -
Intl                          42     37    13.5%    14.1%       -0.6%
WW                            89     80    11.3%    11.6%       -0.3%
PREZISTA
US                            167    160   4.4%     4.4%        -
Intl                          200    164   22.0%    22.3%       -0.3%
WW                            367    324   13.3%    13.5%       -0.2%
OTHER INFECTIOUS DISEASES
US                            24     39    -38.5%   -38.5%      -
Intl                          173    180   -3.9%    -3.0%       -0.9%
WW                            197    219   -10.0%   -9.3%       -0.7%
                                   

                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                                  FIRST QUARTER
                                                % Change
                                   2013   2012  Reported Operational Currency
                                                         ^(1)
NEUROSCIENCE
US                                 746    674   10.7%    10.7%       -
Intl                               998    973   2.6%     5.6%        -3.0%
WW                                 1,744  1,647 5.9%     7.7%        -1.8%
CONCERTA/METHYLPHENIDATE
US                            139    197   -29.4%   -29.4%      -
Intl                          117    111   5.4%     6.8%        -1.4%
WW                            256    308   -16.9%   -16.4%      -0.5%
INVEGA
US                            71     69    2.9%     2.9%        -
Intl                          61     52    17.3%    22.0%       -4.7%
WW                            132    121   9.1%     11.1%       -2.0%
INVEGA SUSTENNA/ XEPLION
US                            164    100   64.0%    64.0%       -
Intl                          120    61    96.7%    96.0%       0.7%
WW                            284    161   76.4%    76.1%       0.3%
RISPERDAL CONSTA
US                            106    113   -6.2%    -6.2%       -
Intl                          229    248   -7.7%    -6.0%       -1.7%
WW                            335    361   -7.2%    -6.0%       -1.2%
OTHER NEUROSCIENCE
US                            266    195   36.4%    36.4%       -
Intl                          471    501   -6.0%    -1.8%       -4.2%
WW                            737    696   5.9%     8.9%        -3.0%
ONCOLOGY
US                                 199    107   86.0%    86.0%       -
Intl                               595    489   21.7%    23.9%       -2.2%
WW                                 794    596   33.2%    35.0%       -1.8%
VELCADE
US                            -      -     -        -           -
Intl                          353    353   0.0%     2.5%        -2.5%
WW                            353    353   0.0%     2.5%        -2.5%
ZYTIGA
US                            161    100   61.0%    61.0%       -
Intl                          183    100   83.0%    83.4%       -0.4%
WW                            344    200   72.0%    72.2%       -0.2%
OTHER ONCOLOGY
US                            38     7     *        *           -
Intl                          59     36    63.9%    68.7%       -4.8%
WW                            97     43    *        *           -4.0%
                                   

                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                                  FIRST QUARTER
                                                % Change
                                   2013   2012  Reported Operational Currency
                                                         ^(1)
TOTAL OTHER
US                                 649    550   18.0%    18.0%       -
Intl                               562    690   -18.6%   -17.5%      -1.1%
WW                                 1,211  1,240 -2.3%    -1.7%       -0.6%
ACIPHEX/PARIET
US                            103    96    7.3%     7.3%        -
Intl                          49     126   -61.1%   -60.5%      -0.6%
WW                            152    222   -31.5%   -31.2%      -0.3%
PROCRIT/EPREX
US                            233    204   14.2%    14.2%       -
Intl                          145    172   -15.7%   -15.8%      0.1%
WW                            378    376   0.5%     0.5%        0.0%
XARELTO
US                            158    27    *     *         -
Intl                          -      -     -        -           -
WW                            158    27    *     *         -
OTHER
US                            155    223   -30.5%   -30.5%      -
Intl                          368    392   -6.1%    -4.4%       -1.7%
WW                            523    615   -15.0%   -13.9%      -1.1%
TOTAL PHARMACEUTICAL
US                                 3,471  3,026 14.7%    14.7%       -
Intl                               3,297  3,107 6.1%     8.1%        -2.0%
WW                                 $     6,133 10.4%    11.4%       -1.0%
                                   6,768
Supplemental Sales Information
                                   2012
                                   Q1     Q2    Q3       Q4          Full Year
INCIVO
US                                 -      -     -        -           -
Intl                               132    102   71       138         443
WW                                 132    102   71       138         443
XARELTO
US                                 27     49    68       95          239
Intl                               -      -     -        -           -
WW                                 27     49    68       95          239
See footnotes at end of schedule
                                   

                                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                                  FIRST QUARTER
                                                % Change
                                   2013   2012  Reported Operational Currency
                                                         ^(1)
MEDICAL DEVICES AND DIAGNOSTICS
^(2)
CARDIOVASCULAR CARE
US                                 $    176   12.5%    12.5%       -
                                   198
Intl                               315    306   2.9%     6.2%        -3.3%
WW                                 513    482   6.4%     8.5%        -2.1%
DIABETES CARE
US                                 283    352   -19.6%   -19.6%      -
Intl                               317    318   -0.3%    0.9%        -1.2%
WW                                 600    670   -10.4%   -9.8%       -0.6%
DIAGNOSTICS
US                                 248    253   -2.0%    -2.0%       -
Intl                               229    259   -11.6%   -7.9%       -3.7%
WW                                 477    512   -6.8%    -4.9%       -1.9%
INFECTION PREVENTION/OTHER
US                                 85     116   -26.7%   -26.7%      -
Intl                               127    128   -0.8%    4.1%        -4.9%
WW                                 212    244   -13.1%   -10.5%      -2.6%
ORTHOPAEDICS
US                                1,261  783   61.0%    61.0%       -
Intl                               1,124  710   58.3%    60.5%       -2.2%
WW                                 2,385  1,493 59.7%    60.7%       -1.0%
SPECIALTY SURGERY
US                                 319    327   -2.4%    -2.4%       -
Intl                               308    301   2.3%     4.7%        -2.4%
WW                                 627    628   -0.2%    1.0%        -1.2%
SURGICAL CARE
US                                 531    593   -10.5%   -10.5%      -
Intl                               977    1,032 -5.3%    -2.4%       -2.9%
WW                                 1,508  1,625 -7.2%    -5.4%       -1.8%
VISION CARE
US                                 281    277   1.4%     1.4%        -
Intl                               459    480   -4.4%    1.6%        -6.0%
WW                                 740    757   -2.2%    1.6%        -3.8%
TOTAL MEDICAL DEVICES AND
DIAGNOSTICS
US                                 3,206  2,877 11.4%    11.4%       -
Intl                               3,856  3,534 9.1%     12.2%       -3.1%
WW                                 $     6,411 10.2%    11.9%       -1.7%
                                   7,062
* Percentage greater than 100%
(1) Operational growth excludes the effect of
currency
(2) Select areas (unaudited)
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year
product disclosure





SOURCE Johnson & Johnson

Website: http://www.jnj.com
Contact: Press Contacts: Ernie Knewitz, (732) 524-6623, (917) 697-2318 (M) or
Al Wasilewski, (732) 524-1130, (732) 447-5918 (M); or Investor Contacts:
Louise Mehrotra, (732) 524-6491 or Lesley Fishman, (732) 524-3922
 
Press spacebar to pause and continue. Press esc to stop.